HUP0104646A2 - Fuzionált 1,2,4-tiadiazin-származékok, azok előállítása és felhasználása - Google Patents
Fuzionált 1,2,4-tiadiazin-származékok, azok előállítása és felhasználásaInfo
- Publication number
- HUP0104646A2 HUP0104646A2 HU0104646A HUP0104646A HUP0104646A2 HU P0104646 A2 HUP0104646 A2 HU P0104646A2 HU 0104646 A HU0104646 A HU 0104646A HU P0104646 A HUP0104646 A HU P0104646A HU P0104646 A2 HUP0104646 A2 HU P0104646A2
- Authority
- HU
- Hungary
- Prior art keywords
- substituents
- alkyl
- compounds
- aryl group
- carbon
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 2
- 150000008337 1,2,4-thiadiazines Chemical class 0.000 title 1
- 125000001424 substituent group Chemical group 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
- -1 hydroxy- Chemical class 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- GTXNMWGIURLXMT-UHFFFAOYSA-N 2h-thieno[3,2-e][1,2,4]thiadiazine Chemical class N1C=NSC2=C1C=CS2 GTXNMWGIURLXMT-UHFFFAOYSA-N 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 210000000748 cardiovascular system Anatomy 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000000750 endocrine system Anatomy 0.000 abstract 1
- 210000005095 gastrointestinal system Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 125000000165 tricyclic carbocycle group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Abstract
A jelen tal lm ny t rgy t képezik az (I) ltal nos képletű 4H-tieno[3,2-e]-1,2,4-tiadiazin-sz rmazékok, az ezen vegyületekettartalmazó készítmények, valamint az ezen vegyületek elő llít s raszolg ló elj r sok. Ezek a vegyületek hasznosak a k"zpontiidegrendszer, a szív- és érrendszer, a tüdőrendszer, a gyomor-bélrendszer és az endokrinrendszer betegségeinek a kezelése sor n. Az(I) ltal nos képletben az X és az Y jelentése egym stól függetlenülhidrogénatom, halogénatom, perahlogén-metil-, 1-6 szénatomos alkil-vagy 1-6 szénatomos alkoxicsoport; az R1, az R2 és az R3 jelentéseegym stól függetlenül 1-6 szénatomos alkil-, 2-6 szénatomos alkenil-,2-6 szénatomos alkinil-, 3-6 szénatomos cikloalkil-, karboxi-, (1-6szénatomos alkoxi)-karbonil- vagy arilcsoport, amelyek mindegyikeopcion lisan egy vagy t"bb szubsztituenst tartalmazhat, ahol aszubsztituensek az al bbiak k"zül kerülhetnek ki: halogénatom,hidroxi-, oxo- vagy arilcsoport; vagy az R1 jelentése megfelel a fentdefini ltaknak, és az R2-C-R3 egy 3-6 szénatomos cikloalkilcsoportotalkot, amely opcion lisan egy vagy t"bb szubsztituenst tartalmazhat,ahol a szubsztituensek az al bbiak k"zül kerülhetnek ki: halogénatom,1-6 szénatomos alkil-, perhalogén-metil-, hidroxi- vagy arilcsoport;vagy a -CR1R2R3 egy 4-12 tagú, biciklusos vagy triciklusoskarbociklusos rendszert alkot, amely opcion lisan egy vagy t"bbszubsztituenst tartalmazhat, ahol a szubsztituensek az al bbiak k"zülkerülhetnek ki: halogénatom, 1-6 szénatomos alkil-, perhalogén-metil-,hidroxi- vagy arilcsoport. Ó
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA199801693 | 1998-12-18 | ||
DKPA199900018 | 1999-01-11 | ||
PCT/DK1999/000702 WO2000037474A1 (en) | 1998-12-18 | 1999-12-15 | Fused 1,2,4-thiadiazine derivatives, their preparation and use |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0104646A2 true HUP0104646A2 (hu) | 2002-04-29 |
HUP0104646A3 HUP0104646A3 (en) | 2004-05-28 |
Family
ID=26063128
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0104646A HUP0104646A3 (en) | 1998-12-18 | 1999-12-15 | Fused 1,2,4-thiadiazine derivatives, their preparation and use |
Country Status (18)
Country | Link |
---|---|
EP (2) | EP1338600A1 (hu) |
JP (1) | JP2002533347A (hu) |
KR (1) | KR20010086126A (hu) |
CN (1) | CN1137125C (hu) |
AT (1) | ATE242254T1 (hu) |
AU (1) | AU1649900A (hu) |
BR (1) | BR9916279A (hu) |
CA (1) | CA2353907A1 (hu) |
CZ (1) | CZ20011831A3 (hu) |
DE (1) | DE69908648T2 (hu) |
DK (1) | DK1140945T3 (hu) |
ES (1) | ES2200575T3 (hu) |
HU (1) | HUP0104646A3 (hu) |
IL (1) | IL143402A0 (hu) |
NO (1) | NO20012966L (hu) |
PL (1) | PL348237A1 (hu) |
PT (1) | PT1140945E (hu) |
WO (1) | WO2000037474A1 (hu) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001265841A1 (en) * | 2000-06-26 | 2002-01-08 | Novo-Nordisk A/S | Use of potassium channel openers for the treatment of insulitis |
WO2002000223A1 (en) * | 2000-06-26 | 2002-01-03 | Novo Nordisk A/S | Use of potassium channel agonists for reducing fat food comsumption |
AU2002221577A1 (en) * | 2000-12-21 | 2002-07-01 | Novo-Nordisk A/S | A new process for preparing fused 1,2,4-thiadiazine derivatives |
WO2003080556A1 (fr) | 2001-01-19 | 2003-10-02 | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. | Derive d'amine a fonction regulatrice des canaux potassiques, sa preparation et son utilisation |
JP4563675B2 (ja) | 2001-10-12 | 2010-10-13 | ハイ・ポイント・ファーマスーティカルズ、エルエルシー | 置換ピペリジン類、およびヒスタミンh3受容体関連疾患の治療のためのその使用 |
AU2002365289A1 (en) * | 2001-11-30 | 2003-06-10 | Novo Nordisk A/S | Use of selective potassium channel openers |
AU2002342600A1 (en) * | 2001-11-30 | 2003-06-10 | Novo Nordisk A/S | Use of selective potassium channel openers |
BR0215212A (pt) | 2001-12-21 | 2004-12-07 | Novo Nordisk As | Ativador de carboxamida ou sulfonamida de glicoquinase, composto, composição farmacêutica, e, uso de um composto |
WO2003105896A1 (en) * | 2002-06-14 | 2003-12-24 | Novo Nordisk A/S | Combined use of a modulator of cd3 and a beta cell resting compound |
KR101116627B1 (ko) | 2002-06-27 | 2012-10-09 | 노보 노르디스크 에이/에스 | 치료제로서 아릴 카르보닐 유도체 |
WO2004005299A1 (en) * | 2002-07-04 | 2004-01-15 | Novo Nordisk A/S | Polymorphic forms of a 4h-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivative |
MXPA06003474A (es) | 2003-09-30 | 2006-06-05 | Novo Nordisk As | Agonistas de receptores de melanocortina. |
EP1694356B1 (en) | 2003-12-09 | 2011-02-16 | Novo Nordisk A/S | Regulation of food preference using glp-1 agonists |
DK1723128T3 (da) | 2004-01-06 | 2013-02-18 | Novo Nordisk As | Heteroarylurinstoffer og deres anvendelse som glucokinaseaktivatorer |
CN1950078A (zh) | 2004-06-11 | 2007-04-18 | 诺和诺德公司 | 使用glp-1激动剂抵抗药物诱发的肥胖 |
JP4874989B2 (ja) | 2004-11-22 | 2012-02-15 | ノヴォ ノルディスク アー/エス | 可溶性で安定なインスリン含有調合物 |
CA2590720A1 (en) | 2004-12-03 | 2006-06-08 | Lone Jeppesen | Heteroaromatic glucokinase activators |
WO2006082204A1 (en) | 2005-02-02 | 2006-08-10 | Novo Nordisk A/S | Insulin derivatives |
US20080171695A1 (en) | 2005-02-02 | 2008-07-17 | Novo Nordisk A/S | Insulin Derivatives |
AP2007004161A0 (en) | 2005-04-28 | 2007-10-31 | Pfizer Ltd | Amino acid derivatives |
AU2006264966B2 (en) | 2005-07-04 | 2013-02-21 | High Point Pharmaceuticals, Llc | Histamine H3 receptor antagonists |
JP4960355B2 (ja) | 2005-07-14 | 2012-06-27 | ノボ・ノルデイスク・エー/エス | ウレア型グルコキナーゼ活性化剤 |
ES2426345T3 (es) | 2005-07-20 | 2013-10-22 | Eli Lilly And Company | Compuesto unidos en posición 1-amino |
PL1951658T3 (pl) | 2005-11-17 | 2013-02-28 | Lilly Co Eli | Antagoniści receptora glukagonu, preparatyka i zastosowania terapeutyczne |
KR101280333B1 (ko) | 2006-03-28 | 2013-07-02 | 하이 포인트 파마슈티칼스, 엘엘씨 | 히스타민 h3 수용체 활성을 갖는 벤조티아졸 |
CN100500672C (zh) * | 2006-04-20 | 2009-06-17 | 山东大学 | N1,N3-二取代噻吩并[3,2-e][2,1,3]噻二嗪-2,2,4-三酮类衍生物与应用 |
CA2659570C (en) | 2006-05-29 | 2015-10-06 | High Point Pharmaceuticals, Llc | 3-(1,3-benzodioxol-5-yl)-6-(4-cyclopropylpiperazin-1-yl)-pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist |
ES2377322T3 (es) | 2006-11-15 | 2012-03-26 | High Point Pharmaceuticals, Llc | Nuevas 2-(2-hidroxifenil)benzotiadiazinas útiles para el tratamiento de la obesidad y la diabetes |
AU2008204530B2 (en) | 2007-01-11 | 2013-08-01 | Vtv Therapeutics Llc | Urea glucokinase activators |
BR112012021231A2 (pt) | 2010-02-26 | 2015-09-08 | Basf Plant Science Co Gmbh | método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto |
US20130012432A1 (en) | 2010-02-26 | 2013-01-10 | Novo Nordisk A/S | Peptides for Treatment of Obesity |
RU2559320C2 (ru) | 2010-03-26 | 2015-08-10 | Ново Нордиск А/С | Новые аналоги глюкагона |
AU2012234276A1 (en) | 2011-03-28 | 2013-08-29 | Novo Nordisk A/S | Novel glucagon analogues |
TWI596110B (zh) | 2011-09-23 | 2017-08-21 | 諾佛 儂迪克股份有限公司 | 新穎升糖素類似物 |
WO2014093696A2 (en) | 2012-12-12 | 2014-06-19 | Massachusetts Institute Of Technology | Insulin derivatives for diabetes treatment |
WO2014170496A1 (en) | 2013-04-18 | 2014-10-23 | Novo Nordisk A/S | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
CN106536547A (zh) | 2014-06-04 | 2017-03-22 | 诺和诺德股份有限公司 | 用于医疗用途的glp‑1/胰高血糖素受体共激动剂 |
EP3201204B1 (en) * | 2014-10-03 | 2021-02-24 | Merck Sharp & Dohme Corp. | C5-c6-fused tricyclic iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
CN111032680A (zh) | 2017-03-15 | 2020-04-17 | 诺和诺德股份有限公司 | 能够与黑皮质素4受体结合的双环化合物 |
WO2019219714A1 (en) | 2018-05-15 | 2019-11-21 | Novo Nordisk A/S | Compounds capable of binding to melanocortin 4 receptor |
WO2020053414A1 (en) | 2018-09-14 | 2020-03-19 | Novo Nordisk A/S | Bicyclic compounds capable of acting as melanocortin 4 receptor agonists |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9707003A (pt) * | 1996-01-17 | 1999-07-20 | Novo Nordisk As | Composto processos para preparar o mesmo para tratamento ou de prevenção de doenças do sistema endócrino e para a manufatura de medicamento coposção farmacêutica e utilização de um composto |
EP1000066A1 (en) * | 1997-07-16 | 2000-05-17 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine derivatives, their preparation and use |
-
1999
- 1999-12-15 HU HU0104646A patent/HUP0104646A3/hu unknown
- 1999-12-15 PL PL99348237A patent/PL348237A1/xx not_active Application Discontinuation
- 1999-12-15 CZ CZ20011831A patent/CZ20011831A3/cs unknown
- 1999-12-15 BR BR9916279-2A patent/BR9916279A/pt not_active IP Right Cessation
- 1999-12-15 JP JP2000589544A patent/JP2002533347A/ja active Pending
- 1999-12-15 KR KR1020017007713A patent/KR20010086126A/ko not_active Application Discontinuation
- 1999-12-15 AT AT99959255T patent/ATE242254T1/de active
- 1999-12-15 CN CNB998144894A patent/CN1137125C/zh not_active Expired - Fee Related
- 1999-12-15 AU AU16499/00A patent/AU1649900A/en not_active Abandoned
- 1999-12-15 WO PCT/DK1999/000702 patent/WO2000037474A1/en not_active Application Discontinuation
- 1999-12-15 ES ES99959255T patent/ES2200575T3/es not_active Expired - Lifetime
- 1999-12-15 EP EP03006331A patent/EP1338600A1/en not_active Withdrawn
- 1999-12-15 PT PT99959255T patent/PT1140945E/pt unknown
- 1999-12-15 CA CA002353907A patent/CA2353907A1/en not_active Abandoned
- 1999-12-15 DK DK99959255T patent/DK1140945T3/da active
- 1999-12-15 IL IL14340299A patent/IL143402A0/xx unknown
- 1999-12-15 DE DE69908648T patent/DE69908648T2/de not_active Expired - Fee Related
- 1999-12-15 EP EP99959255A patent/EP1140945B1/en not_active Expired - Lifetime
-
2001
- 2001-06-15 NO NO20012966A patent/NO20012966L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20012966D0 (no) | 2001-06-15 |
WO2000037474A1 (en) | 2000-06-29 |
DE69908648T2 (de) | 2004-05-13 |
DE69908648D1 (de) | 2003-07-10 |
NO20012966L (no) | 2001-06-15 |
EP1338600A1 (en) | 2003-08-27 |
CZ20011831A3 (cs) | 2001-10-17 |
AU1649900A (en) | 2000-07-12 |
ATE242254T1 (de) | 2003-06-15 |
EP1140945B1 (en) | 2003-06-04 |
KR20010086126A (ko) | 2001-09-07 |
CN1137125C (zh) | 2004-02-04 |
CA2353907A1 (en) | 2000-06-29 |
EP1140945A1 (en) | 2001-10-10 |
PL348237A1 (en) | 2002-05-20 |
BR9916279A (pt) | 2001-10-16 |
IL143402A0 (en) | 2002-04-21 |
HUP0104646A3 (en) | 2004-05-28 |
PT1140945E (pt) | 2003-10-31 |
ES2200575T3 (es) | 2004-03-01 |
CN1330655A (zh) | 2002-01-09 |
JP2002533347A (ja) | 2002-10-08 |
DK1140945T3 (da) | 2003-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0104646A2 (hu) | Fuzionált 1,2,4-tiadiazin-származékok, azok előállítása és felhasználása | |
HUP0105081A2 (hu) | Triazolo[4,5-d]pirimidin-származékok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
HUP0402311A2 (hu) | Naftiridinszármazékok, eljárás előállításukra, és alkalmazásuk foszfodiészteráz izoenzim 4 (PDE4) gátló hatóanyagként és ezeket tartalmazó gyógyszerkészítmények | |
HUP0004333A2 (hu) | Új triazolo [4,5-d] pirimidin-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP9900006A2 (hu) | Ciklikus GMP-specifikus foszfo-diészteráz inhibitor vegyületek, előállításuk és ezeket tartalmazó gyógyszerkészítmények | |
HUP0402336A2 (hu) | Tieno[2,3-d]pirimidin-2,4-dion-származékok, eljárás előállításukra, alkalmazásuk autoimmun betegségek modulálására és a vegyületeket tartalmazó gyógyszerkészítmények | |
HUP0102422A2 (hu) | Rákellenes hatású izotiazolszármazékok, ilyen vegyületeket tartalmazó gyógyszerkészítmények és az előállítási eljárások | |
HUP0001802A2 (hu) | Pirazin-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények | |
HUP9902471A2 (hu) | Piperazin- és piperidinvegyületek, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények | |
HUP0301120A2 (hu) | Szubsztituált fenilamino-kinazolin-származékok, alkalmazásuk rendellenes sejtnövekedés kezelésére és azokat tartalmazó gyógyszerkészítmények | |
HUP0001848A2 (hu) | NOS gátló 6-fenil-piridil-2-amin származékok | |
HUP0204246A2 (hu) | Új tiazolo[4,5-d]pirimidin-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0303729A2 (hu) | Akridinszármazékok és azok gyógyszerként történő alkalmazása és eljárás az előállításukra | |
HUP0302284A2 (hu) | Egy triazolo[4,5-d]pirimidin-vegyület új kristályos és amorf formái | |
HUP0003700A2 (hu) | Kondenzált gyűrűs szubsztituenseket tartalmazó 2-aminopiridinek mint NOS inhibitorok | |
HUP0000562A2 (hu) | Kondenzált pirazolszármazékok, eljárás előállításukra, alkalmazásuk és az azokat tartalmazó gyógyszerkészítmények | |
HUP0002208A2 (en) | Use of sulphonamide derivatives for the preparation of pharmaceutical compositions potentiating glutamate receptor function | |
HUP0003748A2 (hu) | Halogén-szubsztituált tetraciklusos tetrahidrofurán-származékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények | |
TW368501B (en) | 7-(2-aminoethyl)-benzothiazolones | |
BG102701A (en) | 2-hetaroylcyclohexan-1,3-dions | |
HK1115728A1 (en) | Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same | |
HUP0401573A2 (hu) | Eljárás kinazolinszármazékok előállítására | |
HUP0004704A2 (hu) | Dihidrofuro[3,4-b]kinolin-1-on-származékok, eljárás ezek előállítására és ezeket tartalmazó gyógyászati készítmények | |
DE60021286D1 (de) | Verfahren zur herstellung von pyrazolo[1,5-b]pyridazin-derivaten | |
HUP0203364A2 (hu) | Eljárás 3-helyettesített-4-arilkinolin-2-on származékok előállítására |